Background: Latent tuberculosis infection (LTBI) is a critical driver of the global burden of active TB, and therefore LTBI treatment is key for TB elimination. Treatment regimens for LTBI include self-administered daily isoniazid for 6 (6H) or 9 (9H) months, self-administered daily rifampicin plus isoniazid for 3 months (3RH), selfadministered daily rifampicin for 4 months (4R) and weekly rifapentine plus isoniazid for 3 months self-administered (3HP-SAT) or administered by a healthcare worker as directly observed therapy (3HP-DOT). Data on the relative cost-effectiveness of these regimens are needed to assist policymakers and clinicians in selecting an LTBI regimen.
Introduction
Latent tuberculosis infection (LTBI) affects a quarter (1.7 billion people) of the world's population and is a critical driver of the huge global burden of active TB in all settings. 1 When left untreated, 5%-15% of patients with LTBI will eventually develop active TB, with the risk of progression being highest during the first 2 years following initial infection. 1, 2 Treatment for LTBI to prevent the development of active TB is a necessary precursor to TB elimination, a major target of the End TB Strategy and the Sustainable Development Goals. Indeed, TB elimination is not achievable unless this vast global reservoir of LTBI is addressed. 3 However, preventive therapy for LTBI is considerably underutilized in many settings, and globally the most common approach to LTBI management is serial radiographic surveillance for active TB without preventive treatment. 4, 5 When preventive therapy is indicated, isoniazid (300 mg) self-administered daily for 6 (6H) or 9 (9H) months is the most commonly used regimen for treating LTBI. 6 However, the overall effectiveness of these regimens is limited by low treatment completion rates and severe adverse events (SAEs). 7 Selfadministered daily rifampicin (600 mg) in combination with isoniazid (300 mg) for 3 months (3RH) or self-administered daily rifampicin (600 mg) for 4 months (4R) is also recommended for treating LTBI by WHO. 6 These regimens have higher treatment completion rates and lower rates of SAEs than 6H and 9H. [8] [9] [10] A recent randomized controlled trial found that 4R is comparable to 9H in preventing the progression from LTBI to active TB. 9 Once-weekly rifapentine plus isoniazid (900 mg each) for 3 months (3HP) administered by a healthcare worker as directly observed therapy (DOT) has been shown in a randomized controlled trial to be at least as effective as 9H and to have a much higher treatment completion rate than 9H. 11 The feasibility and acceptability of 3HP-DOT was also supported by a recent pragmatic cohort study. 7 Based on these results, WHO endorsed 3HP-DOT as one of the recommended regimens for LTBI treatment among adults at high risk of active TB who have been in contact with a confirmed drugsusceptible case. 6 However, widespread adoption of 3HP-DOT has been limited by the higher cost of rifapentine compared with isoniazid and rifampicin, and the additional health system costs associated with weekly DOT. In an effort to reduce costs and improve uptake, a randomized controlled trial comparing self-administered therapy (SAT) with 3HP (i.e. 3HP-SAT) with 3HP-DOT showed that 3HP-SAT has a lower treatment completion rate than 3HP-DOT (78% versus 85%). 12 Another study compared 3HP-SAT with 9H and found that 3HP-SAT was cheaper and had higher completion rates. 13 Cost-effectiveness analyses measuring the health outcomes of alternative preventive treatment regimens in relation to their costs are needed to assist policymakers and clinicians in selecting an LTBI regimen. To date, three studies have evaluated the costeffectiveness of 3HP-DOT compared with other treatment regimens for LTBI. [14] [15] [16] These studies did not include 3HP-SAT or all WHO-recommended LTBI treatment regimens, nor did they incorporate the latest data on treatment completion of these regimens. [14] [15] [16] We developed a decision analysis model to investigate the cost-effectiveness of all WHO-recommended regimens for the treatment of LTBI in adults recently infected with Mycobacterium tuberculosis (Mtb).
Materials and methods

Model description
We developed a decision analysis model in TreeAge Pro (version 2018; TreeAge Software Inc., Williamstown, MA, USA) to estimate and compare the costs, health outcomes and cost-effectiveness of six regimens for the treatment of LTBI: 3HP-DOT, 3HP-SAT, 3RH, 4R, 6H and 9H. The baseline scenario against which each of these regimens was assessed was a scenario whereby individuals with LTBI only received serial radiographic surveillance for active TB without preventive treatment. We considered a hypothetical population of 10000 adults with an average initial age of 38 years 12 who had been recently infected with Mtb and recommended for preventive treatment. Figure 1 shows a simplified schematic presentation of the model. Model input parameters are presented in Table 1 .
A Markov cycle duration of 1 year was employed and patient outcomes were tracked from commencement of LTBI treatment for 20 years or until death, whichever occurred earlier. This time horizon was chosen to allow for the delayed reactivation that is characteristic of Mtb, which contributes to patient and health system costs. 17 While undergoing treatment for LTBI, patients had a probability of developing SAEs due to treatment and, as a consequence, experienced a small additional risk of death. 11 During each Markov cycle, patients with LTBI also had a risk of progressing to active TB, which was dependent on the effectiveness of the LTBI regimen administered and the level of treatment completion. Patients who only received serial radiographic surveillance without preventive treatment followed the same pathway as those treated with preventive therapy, except that their probability of having SAEs associated with LTBI treatment was set to zero, and their probability of progression from LTBI to active TB was not adjusted for the effectiveness of LTBI treatment.
We assumed that the risk of progression from LTBI to active TB was highest, at 2.5% per year, during the first 2 years following initial infection and then declined to a constant rate of 0.1% per year in subsequent years. 18 Individuals who developed active TB received treatment for the disease incurred additional costs due to this treatment, and had an additional risk of death. Patients with active TB could be successfully treated, or could experience treatment failure or loss to follow-up. We also included relapsed cases of active TB, defined as a recurrent episode of active TB after a period without TB. 19 For simplicity, we assumed that patients did not reenter care after loss to follow-up or treatment failure, but instead entered a state of chronic TB. Patients with chronic TB could heal spontaneously or die from untreated TB. All individuals had an age-specific annual risk of death from causes unrelated to TB (Table S1 , available as Supplementary data at JAC Online). Reinfection, acquisition of drug resistance and relapse of cured chronic TB were not considered.
For each strategy, we calculated the expected costs; the numbers of incident TB cases, TB-related deaths and SAEs; and QALYs. Furthermore, we estimated incremental cost-effectiveness ratios (ICERs), defined as the additional cost per QALY gained compared with the next least expensive non-dominated strategy. 20 Analyses were conducted from a health system perspective and incorporated the costs of medications, medical supplies, medical personnel time and diagnostic procedures. The cost input values reflect published data in the USA 15, 21 and are presented in 2018 US$. Calculations of cost inputs are presented in Supplementary Methods. Costs and health outcomes were discounted at 3% per annum. A strategy was considered good value for money (i.e. cost-effective) if the ICER was equal to or less than the willingness-to-pay (WTP) threshold of $50000 per QALY gained. 22 As human subjects were not involved, ethics approval was not required for this study.
Uncertainty and sensitivity analysis
Uncertainty analysis was performed with Monte Carlo simulation (5000 iterations) to randomly sample parameters from their distributions ( Table 1) . Cost parameters were assigned c distributions and probabilities were assigned triangular distributions. 39 For each parameter, 5000 samples were drawn independently for each of the 10000 individuals. The simulation process is described in Supplementary Methods. We reported 95% uncertainty ranges (95% URs) around projected point estimates. Univariate sensitivity analysis was also carried out to understand the key ICER drivers and the sensitivity of our results to each variable. The variables that were considered in the sensitivity analysis were the start age of the cohort, probability of progression from LTBI to active TB during the first 2 years following initial infection, probability of hospitalization during treatment for active TB, probability of treatment success for active TB, cost of treatment for active TB, cost of hospitalization during treatment for active TB, cost of treatment for SAEs during LTBI therapy, drug cost per 900 mg dose of rifapentine, and drug costs of the LTBI treatment regimens. Table 2 shows the projected costs and health outcomes of the simulated strategies. Compared with the scenario of serial radiographic surveillance without preventive treatment, administration of 3HP-DOT, 3HP-SAT, 4R, 3RH, 9H or 6H would avert 496 (82% reduction relative to serial radiographic surveillance only), 470 (78%), 442 (73%), 418 (69%), 370 (61%) or 276 (46%) incident Cost-effectiveness of latent TB infection treatment JAC cases of active TB per 10000 patients over 20 years, respectively ( Figure 2 ). The cost-effectiveness plane for the regimens is shown in Figure 3 . All regimens were cost saving (i.e. they reduced costs and increased QALYs) compared with serial radiographic surveillance only (Table 2, Figure 3 ). 3HP-SAT was the cheapest regimen and had higher QALYs than all other regimens except 3HP-DOT, which increased QALYs relative to 3HP-SAT at an additional cost of $27948 (95% UR 18089-46330) per QALY gained (Table 2, Figure 3 ). The cost-effectiveness plane for the ICERs of 3HP-DOT relative to 3HP-SAT is presented in Figure 4 . The plane highlights the uncertainty around the results due to simultaneous variations in input parameters. The majority (74%) of the simulated ICERs were below the WTP threshold of $50000 per QALY gained (i.e. 3HP-DOT was more cost-effective than 3HP-SAT).
Results
The cost-effectiveness acceptability curve ( Figure S1 ) represents the probability of a regimen being cost-effective relative to all other regimens over a range of WTP thresholds. The curve shows that the likelihood that 3HP-DOT was cost-effective at a WTP threshold of $50000 per QALY gained was 66%. At this threshold, the probabilities that 3HP-SAT and 4R were costeffective were 22% and 12%, respectively, whereas the remaining regimens had a negligible probability of being cost-effective. 3HP-DOT remained more likely to be cost-effective than 3HP-SAT at a WTP threshold of $28000 per QALY gained. Below this threshold, 3HP-SAT was more likely to be cost-effective than 3HP-DOT ( Figure S1 ).
Univariate sensitivity analyses of key parameters and their impact on the costs and QALYs per patient of each treatment regimen are shown in Figure S2 . For all regimens, the total QALYs per patient were mostly influenced by the start age of the cohort ( Figure S2a ). Higher age at the start of treatment was associated with lower total QALYs. Costs per patient were strongly influenced by the probability of hospitalization during treatment for active TB and the risk of progression to active TB ( Figure S2b and c) . Figure 5 shows the impact of changes in input values of key parameters on 
Continued
Cost-effectiveness of latent TB infection treatment JAC the ICERs of 3HP-DOT relative to 3HP-SAT. The cost-effectiveness of 3HP-DOT relative to 3HP-SAT was most sensitive to the treatment completion rate and the risk of progression from LTBI to active TB. A lower risk of progression to active TB led to reduced cost-effectiveness of 3HP-DOT. Threshold analysis shows that the treatment completion rate of 3HP-DOT needed to be at least 83% (base-case value 85%) for this regimen to be more cost-effective than 3HP-SAT at a WTP threshold of $50000 per QALY gained ( Figure S3 ). With both regimens incorporating rifapentine, the cost per dose of rifapentine had a negligible impact on the relative costeffectiveness ( Figure 5 ).
Discussion
This study is the first to compare the cost-effectiveness of all current WHO-recommended regimens for LTBI treatment. Compared with serial radiographic surveillance, all the regimens prevented additional cases of active TB, reduced costs and increased the total QALYs. Among the alternative regimens, all regimens were more expensive with fewer QALYs than 3HP-SAT from a health system perspective, except 3HP-DOT, which was more effective (higher QALYs) than 3HP-SAT at an additional cost of $27948 (95% UR $18089-$46330) per QALY gained. The drug costs of 3HP-DOT are greater than all other regimens, due mainly to the combination of higher cost of rifapentine and the administration of DOT by healthcare personnel. However, as 3HP-DOT prevents more incident cases of active TB, it was found to be more cost-effective than the same regimen when self-administered (i.e. 3HP-SAT). Although our conclusions on the cost-effectiveness were based on a WTP threshold of $50000 per QALY gained, 3HP-DOT would remain more cost-effective at any WTP $28000 per QALY gained. Furthermore, by providing numerical results of the ICERs, our study allows the determination of the cost-effectiveness of a treatment regimen against any WTP threshold value. Our findings are consistent with previous studies that have investigated the cost-effectiveness of 3HP-DOT for LTBI treatment, showing that 3HP-DOT is highly cost-effective. [14] [15] [16] In addition, we found that the cost-effectiveness of 3HP-DOT was strongly driven by treatment completion rates. For 3HP-DOT to be cost-effective relative to 3HP-SAT, completion rates of at least 83% (base-case value 85%) are required. While this level of adherence has been shown to be achievable in clinical trials and pragmatic studies in high-income countries, 11, 12 it might be a challenge in resourceconstrained settings that have poor healthcare infrastructure, barriers to healthcare access and shortage of healthcare personnel. The cost-effectiveness of 3HP-DOT relative to 3HP-SAT was also sensitive to the risk of progression to active TB, with greater costeffectiveness among patients with a high risk of progression. This is 
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because increasing the underlying risk of progression results in more incident cases of active TB and therefore higher total costs, with the smallest cost increases accruing in regimens that prevent the greatest number of incident cases. Future cost-effectiveness studies that explicitly model outcomes for populations with high risk of disease progression, such as young children, migrants from high TB-burden countries and those with HIV, are needed.
Our study is the first to model the cost-effectiveness of 3HP-SAT. Although 3HP-SAT was not as cost-effective as 3HP-DOT at a WTP threshold of $50000 per QALY gained, it reduced health system costs and increased QALYs compared with serial radiographic surveillance and all other regimens (4R, 3RH, 6H and 9H), such that self-administration of 3HP is also an appealing option. This is particularly important in settings where the capacity to deliver Cost-effectiveness of latent TB infection treatment Relative to the next least expensive, non-dominated strategy.
JAC
b Dominated because the strategy was more expensive and had fewer QALYs than the next least expensive, non-dominated strategy.
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therapy under direct observation is limited. Our results suggest that, in the case where health systems are not willing to pay more than $28000 for an additional QALY gained, 3HP-SAT would be the regimen of choice. Our base-case analysis assumed that the cost per 900 mg dose of rifapentine was $6, based on current public health pricing in the USA. In sensitivity analysis, we allowed this variable to vary between $3 and $12.31 and found that the costeffectiveness of 3HP-DOT and 3HP-SAT was only modestly influenced by the acquisition cost of rifapentine. Even when a higher price of 900 mg rifapentine of $12.31 was used, 3HP-DOT and 3HP-SAT still dominated all other regimens. Although we found 6H and 9H to be less cost-effective relative to all other regimens, these regimens may still be appropriate in instances where rifamycins (e.g. rifampicin, rifapentine) are contraindicated, such as in patients with a history of hypersensitivity to rifamycins and those receiving antiretroviral protease inhibitors.
14 As this analysis was conducted from a health system perspective, only direct medical costs were included. We did not include indirect costs associated with 3HP-DOT administration such as time off work and travel costs. If a societal perspective were used and these additional costs included, we anticipate that the costeffectiveness of 3HP-DOT would be less favourable. In order to quantify uncertainty, we used various sources to determine the parameter values and their plausible ranges, and our conclusions remained unchanged regardless of the uncertainty in parameter values.
This study has some limitations. As with all models, ours is a deliberate simplification of reality. Therefore, it should be noted that the following aspects of TB care were not considered: reinfection, acquisition of drug resistance, and re-treatment for active TB after treatment failure or loss to follow-up. The epidemiological and cost input values in our model are applicable to the USA and comparable settings. As programme costs and epidemiological parameters can vary widely by setting, care should be taken when extrapolating our findings to other settings. In settings where costs of TB treatment are mainly the responsibility of the patient, the costs incurred by the health system would be lower than the values used in our study, and we anticipate that treatment completion rates would also be lower. 40 These costs and treatment completion rates are likely to be equivalently lower in all regimens, and therefore the relative cost-effectiveness would remain the same. Nevertheless, our model can be readily adapted to changing costs and other key variables to fit local conditions.
In conclusion, 3HP-SAT and 3HP-DOT for LTBI treatment are more cost-effective compared with other regimens from a health system perspective. Local and individual circumstances such as the availability of drugs, healthcare personnel, programme feasibility, patient's preference, and perceived risk of progression to active TB need to be considered when selecting a regimen that is suitable for individual patients. Greater recognition of the potential 
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